1,218 reports of this reaction
2.2% of all DASATINIB reports
#11 most reported adverse reaction
OFF LABEL USE is the #11 most commonly reported adverse reaction for DASATINIB, manufactured by E.R. Squibb & Sons, L.L.C.. There are 1,218 FDA adverse event reports linking DASATINIB to OFF LABEL USE. This represents approximately 2.2% of all 55,495 adverse event reports for this drug.
Patients taking DASATINIB who experience off label use should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
OFF LABEL USE is a less commonly reported adverse event for DASATINIB, but still significant enough to appear in the safety profile.
In addition to off label use, the following adverse reactions have been reported for DASATINIB:
The following drugs have also been linked to off label use in FDA adverse event reports:
OFF LABEL USE has been reported as an adverse event in 1,218 FDA reports for DASATINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
OFF LABEL USE accounts for approximately 2.2% of all adverse event reports for DASATINIB, making it a notable side effect.
If you experience off label use while taking DASATINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.